請更新您的瀏覽器
您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。
啟用Javascript
請在瀏覽器上啟用JavaScript來瀏覽頁面中的所有內容。
登入
A Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Included in the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs
PR Newswire (美通社)
傳送
熱門
最多關注
最新
沒有留言。
A Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Included in the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs